CPT-11 in gastrointestinal cancer

European Journal of Cancer

Volumn 35, Issue 3, 1999, Pages 371-379

  Bleiberg, H ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Cancer; Chemotherapy; Colorectal; Gastric; Gastrointestinal; Irinotecan; Metastatic; Pancreatic; Second line

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; META ANALYSIS; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 0033105413     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00423-7     Document Type: Review

References (85)

1. Jauch J.W., Heiss M.M., Gruetzner U., et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J. Clin. Oncol. 14:(6):1996;1810-1817.
2. Bleiberg H., Gerard B., Hendlisz A., Jagodzinski R. Non surgical treatment of cancer of the pancreas. J. Chir. 154:(4):1997;169-173.
3. Graf W., Påhlman L., Bergström R., Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br. J. Cancer. 70:1994;559-563.
4. Fages B, Cote C, Gruia G., et al. Tumor response and stabilisation rates are worthwhile surrogate efficacy endpoints in metastatic colorectal cancer (CRC). Analysis of data in 455 5-FU resistant patients treated with CPT11. Proc Am Soc Clin Oncol 1997, 16 (Abstract 1022).
5. Buroker T.R., O'Connell M.J., Wieand H.S., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J. Clin. Oncol. 12:1994;14-20.
6. Bleiberg H., Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur. J. Cancer. 32A:(Suppl. 3):1996;S18-S23.
7. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
8. Tanizawa A., Fujimori A., Fujimori Y., et al. Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. 86:1994;836-842.
9. Van Cutsem E., Cunningham D., Ten Bokkel Huinink W.W., et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur. J. Cancer. 35:1999;54-59.
10. Gupta E., Lestingi T.M., Mick R., et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhoea. Cancer Res. 54:1994;3723-3725.
11. Canal P., Gay C., Dezeuze A., et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J. Clin. Oncol. 14:(10):1996;2688-2695.
12. Abigerges D., Chabot G.G., Armand J., et al. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 13:1995;210-221.
13. Chabot G., Abigerges D., Catimel G., et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol. 6:1995;141-151.
14. Cunningham D., Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer. 29A:1993;2077-2079.
15. Glimelius B., Pahlam L., Graf W. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol. 10:1992;904-911.
16. Bertrand M., Doroshow J.H., Multhauf P., et al. High dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer; a phase II study. J. Clin. Oncol. 4:1986;1058-1061.
17. Leong L, Doroshow J, Akman S., et al. Phase II trial of 5-FU and high dose folinic acid (HDFA) with cisplatin (CDDP) and dipyridamole (DP) in advanced colorectal cancer. Proc Am Soc Clin Oncol 1989, 8 (Abstract 383).
18. Ahlgren J.D., Trocki O., Gullo J.J., et al. Protracted infusion of 5-FU with weekly low dose cisplatin as a second line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. Cancer Invest. 9:1991;27-33.
19. Delap R., Bordurian E., Nazzaro D., et al. PALA plus 5FU in colorectal cancer; pilot clinical study of a convenient outpatient treatment regimen. Proc. Ann. Meet. Am. Assoc. Cancer Res. 34:1993;1694.
20. Armand J.O., Ducreux M., Mahjoubi M., et al. CPT-11 (Irinotecan) in the treatment of colorectal cancer. Eur. J. Cancer. 31A:1995;1283-1287.
21. Cunningham D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur. J. Cancer. 32A:(Suppl. 3):1996;S1-S8.
22. Rougier P., Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin. Oncol. 23:1996;34-41.
23. Van Cutsem E, Rougier Ph, Droz JP, et al. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc Am Soc Clin Oncol 1997, 16 (Abstract 950).
24. Von Hoff DD, Rothenberg ML, Pitot HC, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997, 16 (Abstract 803).
25. Cunningham D., Pyrhönens, James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
26. Rougier P., Van Cutsem E., Bajetta E., et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1413.
27. Catimel G., Chabot G.G., Guastell J.P., et al. Phase I and pharmacokinetic study of irinotecan (CPT 11) administered daily for three consecutive days every three weeks in patients with advanced solid tumours. Ann. Oncol. 6:1995;133-140.
28. De Forni M., Bugat R., Chabot G.G., et al. Phase I and pharmacokinetic study of the camptothecin derivate irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 54:1994;4347-4354.
29. Armand J.P., Extra Y.M., Catimel G., et al. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann. Oncol. 7:(8):1996;837-842.
30. Merrouche Y, Bugat R, Brunet R, et al. High dose acetorphan (HDA) versus acetorphan + loperamide in the treatment of CPT-11 induced diarrhea: preliminary report of a randomised phase II study in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1996, 15 (Abstract 487).
31. Rougier P., Bugat R., Douillard S., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol. 15:1997;251-260.
32. Wasserman B, Myara A, Paumier D, et al. Baseline bilirubin (Bil) and its transient early increase predicts likelihood of severe neutropenia and diarrhea in CPT-11 based chemotherapy. Proc Am Soc Clin Oncol 1997, 16 (Abstract 767).
33. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14(3), 709-715.
34. Bugat R, Rougier P, Brunet P, et al. Clinical efficacy of CPT-11 in patients with inoperable advanced colorectal cancer (CRC): results of a multicentre open phase II study. 5th International Congress on Anti-Cancer Chemotherapy, Paris 1995.
35. Futatsuki K., Wakui A., Nakoa I., et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn. J. Cancer Chemother. 21:(7):1994;1033-1038.
36. Sakata Y, Tsushima K, Ogasawara H, et al. Phase II study of CPT-11, a new inhibitor of topoisomerase I, for advanced gastrointestinal cancers. Proc Recent Adv Chemotherapy 1993, 862-863.
37. Sakata Y., Shimada Y., Yoshino M., et al. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. Jpn. J. Cancer Chemother. 21:(7):1994;1039-1046.
38. Mishima Y, Hirayama R. The role of lymph node surgery in gastric cancer. In Nagayo T, ed. Histogenesis and Precursors of Human Gastric Cancer. New York, Springer, 1986, 17-39.
39. Fukushima M. Adjuvant therapy of gastric cancer: the Japanese experience. Semin. Oncol. 23:1996;369-378.
40. Kern K.A. Gastric cancer: a neoplastic enigma. J. Surg. Oncol. Suppl. 1:1989;34-39.
41. Bleiberg H., Gerard B., Deguiral P. Adjuvant therapy in resectable gastric cancer. Br. J. Cancer. 66:1992;987-991.
42. Wils J., Klein H.O., Wagener D.J.T., et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 9:1991;827-831.
43. Wils J. The treatment of advanced gastric cancer. Semin. Oncol. 23:1996;397-406.
44. Kelsen D.P. Adjuvant and neoadjuvant therapy for gastric cancer. Semin. Oncol. 23:1996;379.
45. Wilke H., Wils J., Rougier P.H. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer (GC). A trial of the EORTC gastrointestinal tract cancer cooperative group and the AIO (Arveitsge-meinschaft Internistische Onkilogie). Proc. Am. Soc. Clin. Oncol. 14:1995;206.
46. Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 8:1997;163-168.
47. Taguchi T. An early phase II clinical study of RP 56976 (docetaxel) in patients with cancer of the gastrointestinal tract. Jpn. J. Cancer Chemother. 21:(14):1994;2431-2437.
48. Sulkes A., Smyth J., Sessa C., et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br. J. Cancer. 70:(2):1994;380-383.
49. Einzig AI, Lipsitz S, Wiernik PH, Benson AB. Phase II trial of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy. The Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 1995, 14 (Abstract 191).
50. Leichman L., Berry B.T. Cisplatin therapy for adenocarcinoma of the stomach. Semin. Oncol. 18:(1 Suppl. 3):1991;25-33.
51. Webb A., Cunningham D., Howard S.J., et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus FAMTX in advanced esophagogastric cancer. J. Clin. Oncol. 15:1997;261-267.
52. Sakata Y, Nakao I, Futatsuki K, et al. Clinical study of CPT-11, camptothecin analogue, on gastrointestinal cancers. 17th International Congress of Chemotherapy, Berlin, 1991 (Abstract 1951).
53. Wakui A., Taguchi T. An early phase II trial of CPT-11 in patients with advanced gastrointestinal cancer. J. Jpn. Soc. Cancer Ther. (Nippon Gan Chiryo Gakkai Shi). 27:(12):1992;2029-2035.
54. Shimada Y. Topoisomerase I inhibitor: combination chemotherapy with CPT-11 in gastrointestinal cancers. 2nd International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, 9-12 January 1995, Köln, Germany (Abstract 37).
55. Yamao T, Shimada Y, Shirao K, et al. Phase I study of CPT-11 combined with sequential 5-FU in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1996, 15 (Abstract 1527).
56. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of CDDP and CPT-11 in metastatic gastric cancer: CPT-ll Study Group for Gastric Cancer. Proc Am Soc Clin Oncol 1997, 16 (Abstract 936).
57. Boring C.C., Squires T.S., Tong T., Montgomery S. Cancer Statistics 1994. Ca. Cancer J. Clin. 44:1994;7.
58. Wagener D.J.T., Verdonk H.E.R., Dirix L.Y., et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group Study. Ann. Oncol. 6:1995;129-132.
59. Ishii H., Okada S., Nose H., et al. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas. 12:(3):1996;267-271.
60. Morrell L.M., Bach A., Richman S.P., et al. A phase II multi-institutional trial of low-dose N-(phosphonoacetyl)-L-aspartate and high dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group Study. Cancer. 67:1991;363-366.
61. Louvet C., Beerblock K., de Gramont A., et al. High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study. Eur. J. Cancer. 29A:1993;1217.
62. DeCaprio J.A., Mayer R.J., Gonin R. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of phase II trial. J. Clin. Oncol. 9:1991;2128-2133.
63. Palmer K.R., Kerr M., Knowles G., et al. Chemotherapy prolongs survival in inoperable pancreatic cancer. Br. J. Surg. 81:1994;882-885.
64. Glimelius B., Hoffman K., Sjöden P.O., et al. Chemotherapy improved survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 7:1996;593-601.
65. Wils J.A., Kok T., Wagener D.J.T.H., Selleslags J., Duez N. Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J. Cancer. 29A:1993;203-204.
66. Loehrer P.J., Williams S.D., Einhorn L.H., Ansari R. Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J. Clin. Oncol. 3:1985;367-372.
67. Cerny T., Martinelli G., Goldhisch A., et al. Continuous 5-day infusion of ifosfamide with messna in inoperable pancreatic cancer patients: a phase II study. J. Cancer Res. Clin. Oncol. 117:1991;S135-S138.
68. Moore M, Andersen J, Burris H, et al. A randomised trial of gemcitabine (Gem) versus 5-FU as first line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1995, 14 (Abstract 199).
69. Rougier PH, De Forni M, Adenis A, et al. Phase II study of Taxotere (RP56976, docetaxel) in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1994, 13 (Abstract 200).
70. Rougier P., Zarba J.J., Ducreux M., et al. Phase II study of cisplatin and 12-hour; continuous infusion of 5-fluorouracil in patients with advanced pancreatic carcinoma. Ann. Oncol. 4:1993;333-336.
71. Sakata Y, Wakui A, Nakao I, et al. A late phase II study of irinotecan (CPT-11), in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1993, 12 (Abstract 633).
72. Saltz L., Shimada Y., Khayat D. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur. J. Cancer. 32A:(3):1996;S24-S31.
73. Saltz L., Kanowitz J., Kemeny N.E., et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumors. J. Clin. Oncol. 14:(11):1996;2959-2967.
74. Rothenberg ML, Pazdur R, Rowinksy EK, et al. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1997 (944); poster presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, Colorado, 17-20 May 1997.
75. Grossin F, Barbault H, Benhammouda A, et al. A phase I pharmacokinetics study of concomitant CPT-11 and 5-FU combination. Proc Am Assoc Can Res 1996, 37, (Abstract 1156).
76. Khayat D, Antoine E, Bastian G, et al. Studies of the combination of irinotecan (CPT-11) and 5-FU for the treatment of advanced colorectal cancer. Presented at 6th EORTC/CITCCG Symposium, Nijmegen, 1996.
77. Benhammouda A, Bastian G, Rixe O, et al. A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5FU (F) combination. Proc Am Soc Clin Oncol 1997, 16 (Abstract 710).
78. Cvitkovic E, Wasserman E, Goldwasser F, et al. Preliminary report on a oxaliplatin (LOHP)/CPT-11 phase I trial in gastrointestinal (GI) malignancies: an active combination. Proc Am Soc Clin Oncol 1997, 16 (Abstract 806).
79. Lokiec F, Wasserman E, Santoni J, et al. Pharmacokinetics (PK) of the irinotecan (CPT 11) oxaliplatin (LOHP) combination: preliminary data of an ongoing phase I trial. Proc Am Soc Clin Oncol 1997, 16 (Abstract 711).
80. Couteau C, Lokiec F, Vernillet L, et al. Phase I dose finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors. Proc Am Soc Clin Oncol 1997, 16 (Abstract 709); poster presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, Colorado, 17-20 May 1997.
81. Verweij J, de Jonge MJA, Sparreboom A, et al. Phase I and pharmacokinetic (PK) study of irinotecan (CPT-11) and cisplatin (C) in patients with solid tumors. Proc Am Soc Clin Oncol (in press).
82. Paz-Ares L, Sastre J, Diaz-Rubio E, et al. Phase I dose finding study of irinotecan (CPT11) over a short IV infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous IV infusion in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1997, 16 (Abstract 874).
83. Ducreux M, Rougier Ph, Ychou M, et al. Phase I/II study of escalating dose of CPT11 in combination with LV5FU2 (De Gramont regimen) every 2 weeks in the treatment of colorectal cancer (CRC) after 5FU failure. Proc Am Soc Clin Oncol 1997, 16 (Abstract 823).
84. Barone C, Pozzo C, Starkhammar H, et al. CPT11 alternating with 5 fluorouracil (5FU) folinic acid (FA): a multicentre phase II study in 1st line chemotherapy (CT) of metastatic colorectal cancer (CRC). Proc ASCO 1997, 16 (Abstract 957); poster presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, Colorado, 17-20 May 1997.
85. Vanhoefer U, Harstrick A, Müller C, et al. Phase I study of a weekly schedule of irinotecan (CPT-11) in combination with high dose folinic acid and 5-fluorouracil as first line chemotherapy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997, 16 (Abstract 967), poster presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, Colorado, 17-20 May 1997.